Tragara Pharmaceuticals Inc.

Tragara Pharmaceuticals Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy. This profile was adapted from an article that first appeared in the July issue of Pharmaceuticals Approval Monthly.

10955 Vista Sorrento Parkway

Suite 120

More from Archive

More from Scrip